[Federal Register Volume 76, Number 90 (Tuesday, May 10, 2011)]
[Notices]
[Pages 27105-27108]
[FR Doc No: 2011-11315]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-64401; File No. SR-Phlx-2011-55]

Self-Regulatory Organizations; NASDAQ OMX PHLX LLC; Notice of
Filing and Immediate Effectiveness of Proposed Rule Change Relating to
In-Crowd Priority

May 4, 2011.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act'') \1\, and Rule 19b-4 \2\ thereunder, notice is hereby given
that, on April 27, 2011, NASDAQ OMX PHLX LLC (``Phlx'' or ``Exchange'')
filed with the Securities and Exchange Commission (``SEC'' or
``Commission'') the proposed rule change as described in Items I and II
below, which Items have been prepared by the Exchange. The Commission
is publishing this notice to solicit comments on the proposed rule
change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to amend Exchange Rule 1014, Commentary
.05(c), Non-Electronic Orders, to state that, respecting crossing,
facilitation and solicited orders with a size of at least 500 contracts
on each side that are represented and executed in open

outcry, priority will continue to be afforded to in-crowd participants
(including, for purposes of this rule only, Floor Brokers) over Remote
Specialists,\3\ Remote Streaming Quote Traders (``RSQTs'') \4\ and out-
of crowd Streaming Quote Traders (``SQTs''),\5\ but not over public
customer orders. The Exchange proposes to amend the rule to state that
in-crowd participants in such orders would also have priority over out-
of-crowd broker-dealer limit orders on the limit order book.
---------------------------------------------------------------------------

    \3\ A Remote Specialist is a qualified RSQT approved by the
Exchange to function as a specialist in one or more options if the
Exchange determines that it cannot allocate such options to a a
floor based specialist. A Remote Specialist has all the rights and
obligations of a specialist, unless Exchange rules provide
otherwise. See Exchange Rules 501 and 1020. See also, Securities
Exchange Act Release No. 63717 (January 14, 2011), 76 FR 4141
(January 24, 2011) (SR-Phlx-2010-145).
    \4\ An RSQT is an ROT that is a member or member organization
with no physical trading floor presence who has received permission
from the Exchange to generate and submit option quotations
electronically in options to which such RSQT has been assigned. An
RSQT may only submit such quotations electronically from off the
floor of the Exchange. See Exchange Rule 1014(b)(ii)(B).
    \5\ An SQT is an Exchange Registered Options Trader (``ROT'')
who has received permission from the Exchange to generate and submit
option quotations electronically in options to which such SQT is
assigned. An SQT may only submit such quotations while such SQT is
physically present on the floor of the Exchange. See Exchange Rule
1014(b)(ii)(A).
---------------------------------------------------------------------------

    The text of the proposed rule change is available on the Exchange's
Web site at http://www.nasdaqtrader.com/micro.aspx?id=PHLXRulefilings,
at the principal office of the Exchange, and at the Commission's Public
Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The purpose of the proposed rule change is to amend Commentary .05
of Rule 1014 to state that in-crowd participants will continue, as
today, to have priority over Remote Specialists, RSQTs and out of crowd
SQTs respecting crossing, facilitation and solicited orders with a size
of at least 500 contracts on each side, and to state that, respecting
such orders, in-crowd participants will now be afforded priority over
out-of-crowd broker-dealer limit orders on the limit order book. The
proposal is also intended to provide that the term ``in-crowd
participants'' includes, for purposes of this rule only, Floor Brokers
representing such orders in open outcry in the trading crowd. In
keeping with current Exchange practices and rules, public customer
limit orders represented in the trading crowd and resting on the limit
order book have, and will continue to have, priority over all other
participants and accordingly must be executed up to the aggregate size
of such orders before any in-crowd participant is entitled to priority.
Current Rule
    Currently, Exchange Rule 1014, Commentary .05 states that
respecting crossing, facilitation and solicited orders \6\ with a size
of at least 500 contracts on each side that are represented and
executed in open outcry, priority is afforded to in-crowd participants
over Remote Specialists, RSQTs and out-of crowd SQTs. The current rule
does not affirmatively afford priority to in-crowd participants over
orders on the limit order book, whether such orders are for public
customers or non-customers. Thus, Floor Brokers representing and
executing crossing, facilitation and solicited orders in open outcry
are required to execute against all marketable orders on the limit
order book before executing against the crowd, because the marketable
orders on the limit order book have time priority.
---------------------------------------------------------------------------

    \6\ See Exchange Rule 1064.
---------------------------------------------------------------------------

The Proposal
    The proposed amendment to the rule would state that the rule also
affords priority to in-crowd participants over out-of out-of-crowd
broker-dealer limit orders on the limit order book. Public customer
orders on the limit order book that are eligible for execution would
still be required to be executed before the Floor Broker could execute
its order in the crowd and/or with a contra-side order it holds. The
proposed rule would also provide that the term ``in-crowd
participants'' includes, for purposes of this rule only, Floor Brokers
representing orders in open outcry in the trading crowd.
    The Exchange believes that this should enable it to compete for
order flow with other exchanges that have similar rules in place
without limiting eligible order types.\7\ The instant proposal will not
affect public customer priority. The Exchange will continue to execute
public customer limit orders up to their aggregate size at a particular
price point.
---------------------------------------------------------------------------

    \7\ The Exchange notes that Chicago Board Options Exchange, Inc.
(``CBOE'') Rule 6.74(d)(vi)) affords priority to in-crowd
participants over out-of-crowd participants, including non-public
customer orders on the limit order book, in all open outcry
situations after public customers on the limit order book have been
executed. See Securities Exchange Act Release No. 54726 (November 8,
2006), 71 FR 66810 (November 16, 2006) (SR-CBOE-2006-89).
---------------------------------------------------------------------------

    The proposed rule change is intended to replicate, in open outcry,
the current electronic trade allocation algorithm applicable to trades
executed and allocated electronically on the Exchange's electronic
trading platform for options, PHLX XL.\8\ Specifically, the Exchange
notes that Exchange Rules 1014(g)(vii) and (viii) both provide that, if
any contracts remain to be allocated after public customers and PHLX XL
participants (including the specialist, SQTs, RSQTs and non-SQT ROTs
with limit orders on the limit order book) that are bidding or offering
at the execution price have received their respective allocations, off-
floor broker-dealers that have placed limit orders on the limit order
book which represent the Exchange's disseminated price are thereafter
entitled to receive any remaining contracts. The instant proposal is
intended to state that this is also the case respecting crossing,
facilitation and solicited orders with a size of at least 500 contracts
on each side that are represented in open outcry.
---------------------------------------------------------------------------

    \8\ In May, 2009 the Exchange enhanced the system and adopted
corresponding rules referring to the system as ``Phlx XL II.'' See
Securities Exchange Act Release No. 59995 (May 28, 2009), 74 FR
26750 (June 3, 2009) (SR-Phlx-2009-32). The Exchange intends to
submit a separate technical proposed rule change that would change
all references to the system from ``Phlx XL II'' to ``PHLX XL'' for
branding purposes.
---------------------------------------------------------------------------

Non-Affiliated Floor Brokers
    The Exchange represents that all of its Floor Brokers are currently
independent business operations and are not affiliated with any other
Exchange member. The Exchange recognizes that if a Floor Broker becomes
affiliated with a member, an issue could arise under Section 11a of the
Act \9\ concerning in-person trading on the Exchange floor. Floor
brokers are able to achieve in-crowd priority in accordance with this
proposal provided, however, that a Floor Broker who is affiliated with
a

PHLX member, and represents an order on behalf of such member, must
ensure that the PHLX member qualifies for an exemption from Section
11(a)(1) of the Exchange Act or that the transaction satisfies the
requirements of Exchange Act Rule 11a2-2(T), otherwise the Floor Broker
must yield priority to orders for the accounts of non-members.
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78k(11)(a).
---------------------------------------------------------------------------

Conclusion
    The Exchange believes that the proposed rule should provide
incentive and liquidity for order flow providers that submit larger
size crossing, facilitation and solicited orders for execution in open
outcry to the Exchange, thus enabling the Exchange to compete with
exchanges that have similar priority rules in effect.\10\
---------------------------------------------------------------------------

    \10\ See supra note 7.
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that its proposal is consistent with Section
6(b) of the Act \11\ in general, and furthers the objectives of Section
6(b)(5) of the Act \12\ in particular, in that it is designed to
promote just and equitable principles of trade, to remove impediments
to and perfect the mechanism of a free and open market and a national
market system, and, in general to protect investors and the public
interest, by adopting a rule that affords priority to in-crowd
participants over out-of-crowd broker-dealer limit orders on the limit
order book in certain crossing, facilitation and solicited orders
represented and executed in open outcry.
---------------------------------------------------------------------------

    \11\ 15 U.S.C. 78f(b).
    \12\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

    The Exchange believes that the proposal promotes just and equitable
principles of trade by retaining customer priority in all cases, and by
affording priority to in-crowd participants who are required to meet
minimum quoting requirements,\13\ and that the proposal removes
impediments to and perfects the mechanism of a free and open market by
improving Floor Brokers' ability to trade crossing, facilitation and
solicited orders with at least 500 contracts on each side, all to the
benefit of customers and the public interest.
---------------------------------------------------------------------------

    \13\ See, e.g., Exchange Rule 1014(b)(ii)(D).
---------------------------------------------------------------------------

    Exchange Rule 1014 currently affords priority to in-crowd
participants over Remote Specialists. A Remote Specialist is first
required to be an RSQT, and the instant proposal would continue to
afford priority to Remote Specialists in the same manner as it provides
such priority over RSQTs. In January 2011, the Commission approved the
Exchange's proposal to amend Commentary .05(c)(i) of Rule 1014 to
establish priority for Remote Specialists that is coextensive with the
priority afforded in that rule to RSQTs and out-of-crowd SQTs.\14\ The
Exchange believes this established priority that treats RSQTs and
Remote Specialists equally is just and equitable, because neither a
Remote Specialist nor an RSQT is required to respond to a Floor Broker
entering the crowd and requesting a market, whereas in-crowd
participants are required to verbalize a market in response to such a
request.\15\
---------------------------------------------------------------------------

    \14\ See Securities Exchange Act Release No. 63717 (January 14,
2011), 76 FR 4141 (January 24, 2011) (SR-Phlx-2010-145).
    \15\ See Exchange Rules 1014(c) and (d).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition not necessary or appropriate in
furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    No written comments were either solicited or received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Pursuant to Section 19(b)(3)(A) \16\ of the Act and Rule 19b-
4(f)(6) \17\ thereunder, the Exchange has designated this proposal as
one that effects a change that: (i) Does not significantly affect the
protection of investors or the public interest; (ii) does not impose
any significant burden on competition; and (iii) by its terms, does not
become operative for 30 days after the date of the filing, or such
shorter time as the Commission may designate if consistent with the
protection of investors and the public interest.
---------------------------------------------------------------------------

    \16\ 15 U.S.C. 78s(b)(3)(A).
    \17\ 17 CFR 240.19b-4(f)(6).
---------------------------------------------------------------------------

    Rule 19b-4(f)(6) requires a self-regulatory organization to give
the Commission written notice of its intent to file the proposed rule
change at least five business days prior to the date of filing of the
proposed rule change, or such shorter time as designated by the
Commission.\18\ The Exchange has satisfied this requirement.
---------------------------------------------------------------------------

    \18\ 17 CFR 240.19b-4(f)(6).
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act. If the Commission
takes such action, the Commission shall institute proceedings to
determine whether the proposed rule should be approved or disapproved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an e-mail to<EMAIL_ADDRESS>Please include
File Number SR-Phlx-2011-55 on the subject line.

Paper Comments

     Send paper comments in triplicate to Elizabeth M. Murphy,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-Phlx-2011-55. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for Web site viewing and
printing in the Commission's Public Reference Room, 100 F Street, NE.,
Washington, DC 20549, on official business days between the hours of 10
a.m. and 3 p.m. Copies of the filing also will be available for
inspection and copying at the principal office of the Exchange. All
comments received will be posted without change; the Commission does
not edit personal identifying information from submissions. You should
submit only information that you wish to make available publicly. All
submissions

should refer to File Number SR-Phlx-2011-55 and should be submitted on
or before May 31, 2011.

For the Commission, by the Division of Trading and Markets, pursuant
to delegated authority.\19\
---------------------------------------------------------------------------

    \19\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Elizabeth M. Murphy,
Secretary.
[FR Doc. 2011-11315 Filed 5-9-11; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 77, Number 24 (Monday, February 6, 2012)]
[Rules and Regulations]
[Pages 5710-5711]
[FR Doc No: 2012-2328]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Parts 52 and 97

[EPA-HQ-OAR-2009-0491; FRL-9626-2]

Federal Implementation Plans for Iowa, Michigan, Missouri,
Oklahoma, and Wisconsin and Determination for Kansas Regarding
Interstate Transport of Ozone: Effect of Stay of Transport Rule

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of Intent.

-----------------------------------------------------------------------

SUMMARY: A December 30, 2011 order of the U.S. Court of Appeals for the
District of Columbia Circuit stayed the Transport Rule, also known as
the Cross State Air Pollution Rule.\1\ This document sets out EPA's
interpretation of the effect of the Court's stay on the federal
implementation plans finalized by EPA on December 15, 2011 (SNFR),
which included the conclusion that Iowa, Kansas, Michigan, Missouri,
Oklahoma, and Wisconsin significantly contribute to nonattainment or
interfere with maintenance of the 1997 ozone National Ambient Air
Quality Standards (NAAQS) in other states and required sources in five
states to comply with the Transport Rule's ozone season NOX
trading program.\2\
---------------------------------------------------------------------------

    \1\ Federal Implementation Plans to Reduce Interstate Transport
of Fine Particulate Matter and Ozone in 27 States; Correction of SIP
Approvals for 22 States: Final Rule (76 FR 48208, August 8, 2011).
Available on the Web at http://www.epa.gov/crossstaterule.
    \2\ EPA did not finalize a FIP for Kansas with respect to the
1997 ozone NAAQS in the SNFR. EPA had previously approved a section
110(a)(2)(D)(i) SIP submission from the state of Kansas for the 1997
ozone and 1997 PM2.5 NAAQS on March 9, 2007 (75 FR
10608), and that SIP submission did not rely on the unlawful CAIR
trading programs or on the conclusion that compliance with CAIR was
sufficient to satisfy its 110(a)(2)(D)(i)(I) obligations with
respect to the 1997 ozone and PM2.5 NAAQS. EPA therefore
did not have the obligation to promulgate a FIP for Kansas under
section 110(c)(1) of the CAA, and instead proposed a SIP Call for
Kansas under section 110(k)(5) of the Act (76 FR 763, January 6,
2011). EPA proposed to find Kansas' SIP substantially inadequate to
meet the requirements of 110(a)(2)(D)(i)(I) with respect to the 1997
ozone NAAQS based on the proposed conclusion that emissions from
Kansas are significantly contributing to nonattainment or
interfering with maintenance of the 1997 ozone NAAQS in another
state. EPA has not taken final action yet on the proposed SIP Call.

---------------------------------------------------------------------------
DATES: The effective date of this notice of intent is February 6, 2012.

FOR FURTHER INFORMATION CONTACT: Gabrielle Stevens, U.S. Environmental
Protection Agency, Clean Air Markets Division, MC 6204J, Ariel Rios
Building, 1200 Pennsylvania Ave. NW., Washington, DC 20460, telephone
(202) 343-9252, email at<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Background

    On July 6, 2011, the EPA issued a final rule promulgating the
Transport Rule (76 FR 48208, August 8, 2011). The Transport Rule limits
the interstate transport of emissions of nitrogen oxides
(NOX) and sulfur dioxide (SO2) that contribute to
harmful levels of fine particulate matter (PM2.5) and ozone
in downwind states. The rule identified emissions within 27 states in
the eastern United States that significantly affect the ability of
downwind states to attain and maintain compliance with the 1997 and
2006 fine particulate matter NAAQS and the 1997 ozone NAAQS. EPA
established trading programs to reduce these emissions through Federal
Implementation Plans (FIPs) that regulate electric generating units
(EGUs) in the 27 states.
    As explained in the preambles to the final Transport Rule (76 FR
48208) and the supplemental notice of final rulemaking (SNFR) (76 FR
80761), EPA updated and improved its modeling platforms and inputs in
response to public comments received on the proposed Transport Rule and
subsequent Notices of Data Availability (NODAs), and performed other
updates. Therefore, some of the results of the analysis performed for
the final Transport Rule differed from the results of the analysis
conducted for the Transport Rule proposal. Under the proposed Transport
Rule, EPA's analysis did not identify Wisconsin, Iowa, and Missouri as
states that significantly contribute to nonattainment and/or interfere
with maintenance of the ozone NAAQS in another state with respect to
the 1997 ozone NAAQS. Under the final Transport Rule's analysis,
however, the results indicated that emissions from these states do
interfere with maintenance of the ozone NAAQS of another state. The
results also showed that emissions from Missouri significantly
contribute to nonattainment of the ozone NAAQS in another state. The
analysis for the final rule also identified two ozone maintenance
receptors, located in Allegan County, Michigan and Harford County,
Maryland, which were not identified by modeling conducted for the
proposed rule. The analysis indicated that five states--Iowa, Kansas,
Michigan, Oklahoma, and Wisconsin--interfered with maintenance problems
at these receptors. EPA did not include

these states in the final Transport Rule with respect to the 1997 ozone
season NAAQS or finalize ozone season NOX budgets for these
states, but instead published a supplemental notice of proposed
rulemaking (SNPR) (76 FR 40662) to provide the public with an
opportunity to comment on the conclusion that these states
significantly contribute to nonattainment or interfere with maintenance
of the 1997 ozone NAAQS in downwind states. EPA finalized the
supplemental notice of proposed rulemaking on December 15, 2011, which
was published in the Federal Register on December 27, 2011 (SNFR) (76
FR 80761). The SNFR found that emissions of NOX from sources
in Iowa, Kansas, Michigan, Missouri, Oklahoma, and Wisconsin either
significantly contributed to nonattainment or interfered with
maintenance in downwind states. The SNFR also finalized FIPs for Iowa,
Michigan, Missouri, Oklahoma, and Wisconsin that required sources
within the states to comply with the Transport Rule.\3\
---------------------------------------------------------------------------

    \3\ EPA did not finalize a FIP for Kansas. See supra footnote 2.
---------------------------------------------------------------------------

    After publication of the final Transport Rule, various parties
filed petitions for review of EPA's action in the U.S. Court of Appeals
for the District of Columbia Circuit (EME Homer City Generation, L.P.
v. EPA, No. 11-1302 and consolidated cases). On December 30, 2011, upon
the motions of various petitioners, the Court ordered the Transport
Rule stayed pending the completion of its review.

II. This Notice of Intent

    The Court did not explicitly address the effect of its order on the
SNFR affecting Iowa, Kansas, Michigan, Missouri, Oklahoma, and
Wisconsin. Because the underlying programs of the Transport Rule have
been stayed by the Court, there is no practical way for covered sources
under the SNFR to comply with those programs. The SNFR employs the same
methodology, modeling, and analysis as the final Transport Rule and
extends the programs established in the Transport Rule to additional
states. The agency will therefore treat the new rule in the same manner
as the underlying Transport Rule, which has been stayed. EPA does not
expect covered sources under the SNFR to comply with the provisions of
that rule for the duration of the Court's stay.

    Dated: January 26, 2012.
Gina McCarthy,
Assistant Administrator.
[FR Doc. 2012-2328 Filed 2-3-12; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register Volume 76, Number 90 (Tuesday, May 10, 2011)]
[Notices]
[Pages 27123-27125]
[FR Doc No: 2011-11325]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-64397; File No. SR-FINRA-2011-019]

Self-Regulatory Organizations; Financial Industry Regulatory
Authority, Inc.; Notice of Filing and Immediate Effectiveness of
Proposed Rule Change To Rename the OTC Bulletin Board in the FINRA
Rulebook

May 4, 2011.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Exchange Act'') \1\ and Rule 19b-4 thereunder,\2\ notice is hereby
given that on April 25, 2011, Financial Industry Regulatory Authority,
Inc. (``FINRA'') filed with the Securities and Exchange Commission
(``SEC'' or ``Commission'') the proposed rule change as described in
Items I and II below, which Items have been prepared by FINRA. FINRA
has designated the proposed rule change as constituting a ``non-
controversial'' rule change under paragraph (f)(6) of Rule 19b-4 under
the Exchange Act,\3\ which renders the proposal effective upon receipt
of this filing by the Commission. The Commission is publishing this
notice to solicit comments on the proposed rule change from interested
persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 17 CFR 240.19b-4(f)(6).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    FINRA is proposing to amend FINRA Rule 6500 Series and Rules 7700,
7720 and 7740 to replace references to ``OTC Bulletin Board'' and
``OTCBB'' with ``Non-NMS Quotation Service'' and ``NNQS.''
    The text of the proposed rule change is available on FINRA's Web
site at http://www.finra.org, at the principal office of FINRA, at the
Commission's Public Reference Room, and on the Commission's Web site at
http://www.sec.gov.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, FINRA included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. FINRA has prepared summaries, set forth in sections A,
B,

and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    As initially announced by FINRA in September 2009, FINRA currently
is seeking to divest itself of the OTCBB trademark, related domain
name, and all informational content from the http://www.OTCBB.com Web
site that is not otherwise required to be retained by FINRA for
regulatory purposes (``OTCBB assets''). FINRA reached agreement with an
entity for the sale of the OTCBB assets in the third quarter of
2010.\4\ In connection with this effort, and to remove certain current
impediments to the completion of such a transaction, FINRA is filing
the proposed rule change to rename the OTC Bulletin Board (``OTCBB'')
as the Non-NMS Quotation Service (``NNQS'').
---------------------------------------------------------------------------

    \4\ See Rodman & Renshaw Capital Group, Inc., Press Release
September 14, 2010 (``Rodman and FINRA Reach Preliminary Agreement
on Terms for Rodman Acquisition of OTCBB Assets'').
---------------------------------------------------------------------------

    The OTCBB assets do not include the technology comprising the
interdealer quotation system operated by FINRA, which is currently
known as ``OTCBB.'' Thus, the renaming of OTCBB as NNQS, as proposed
here, enables FINRA to proceed with the sale of the OTCBB assets by
removing references to OTCBB from the current FINRA Rulebook, while
continuing to permit FINRA to operate its interdealer quotation system
under the new name without change or interruption to the availability
of this service by FINRA. The FINRA Rule 6500 Series will govern the
operation of the NNQS as it currently does for OTCBB, and the
functionality of the NNQS will be identical to that of the current
OTCBB.
    While FINRA has filed the proposed rule change for immediate
effectiveness, the renaming, transitioning of the related domain name,
and consummation of the sale transaction will be implemented at a later
date to be announced by FINRA (the ``implementation date'').\5\
However, the implementation date will be no sooner than 120 days
following the date of filing of the proposed rule change. Until such
implementation date, FINRA will continue to operate the http://www.OTCBB.com Web site and the OTCBB interdealer quotation system in
the same manner as it currently does. Thus, the operation of the OTCBB
facilities as an inter-dealer quotation system by FINRA and support of
the http://www.OTCBB.com Web site will not change in any respect until
the actual implementation date, which is anticipated to be before the
end of 2011, but in no event will be sooner than 120 days following the
date of this filing. Subsequent to the implementation date, FINRA will
continue to operate the NNQS in the same manner it currently operates
the OTCBB, consistent with FINRA's statutory obligations under Section
15A \6\ of the Exchange Act.\7\
---------------------------------------------------------------------------

    \5\ Upon implementation of the proposed rule change, FINRA's
interdealer quotation system will be known as NNQS, and FINRA no
longer will own the http://www.OTCBB.com Web site.
    \6\ 15 U.S.C. 78o-3(b)(11).
    \7\ On August 7, 2009, FINRA filed with the Commission a
proposed rule change to restructure quotation collection and
dissemination for OTC Equity Securities that is currently pending
with the Commission. See Securities Exchange Act Release No. 60999
(November 13, 2009), 74 FR 61183 (November 23, 2009) (``QCF
Proposal''). The instant proposed rule change does not alter FINRA's
current quotation transparency activities in the over-the-counter
market through the operation of an interdealer quotation system
unless the QCF Proposal is approved by the Commission and takes
effect. Thus, unless and until the SEC approves the QCF and it takes
effect, FINRA intends to operate the NNQS after the implementation
date.
---------------------------------------------------------------------------

    Upon the implementation of the proposed rule change, FINRA will
offer data on or through the FINRA Web site that is substantially
equivalent to the type of quotation and last sale data for OTC equity
securities currently available on http://www.OTCBB.com. In addition,
FINRA will undertake a concerted communications campaign to ensure that
the public (including retail investors) is well-informed with respect
to the pending changes. This campaign will include outreach to OTCBB-
quoted issuers regarding the status of their continued eligibility to
quote on the NNQS upon the implementation date.
    FINRA has filed the proposed rule change for immediate
effectiveness. FINRA will announce the implementation date no later
than 270 days following the date of filing of the proposed rule change,
but in no event will be sooner than 120 days following the date of
filing of the proposed rule change.
2. Statutory Basis
    FINRA believes that the proposed rule change is consistent with the
provisions of Section 15A(b)(6) of the Exchange Act,\8\ which requires,
among other things, that FINRA rules must be designed to prevent
fraudulent and manipulative acts and practices, to promote just and
equitable principles of trade, and, in general, to protect investors
and the public interest. Section 15A(b)(11) of the Exchange Act \9\
requires that FINRA rules include provisions governing the form and
content of quotations relating to securities sold otherwise than on a
national securities exchange which may be distributed or published by
any member or person associated with a member, and the persons to whom
such quotations may be supplied. In addition, Section 15A(b)(11) of the
Exchange Act \10\ requires that such rules be designed to produce fair
and informative quotations, to prevent fictitious or misleading
quotations, and to promote orderly procedures for collecting,
distributing, and publishing quotations.
---------------------------------------------------------------------------

    \8\ 15 U.S.C. 78o-3(b)(6).
    \9\ 15 U.S.C. 78o-3(b)(11).
    \10\ Id.
---------------------------------------------------------------------------

    FINRA believes the proposed rule change is consistent with Section
15A(b)(6) and (11) of the Exchange Act in that it facilitates FINRA's
continued ability to operate an interdealer quotation system for use by
market makers in OTC equity securities that is functionally identical
to the service provided under the current name, thereby supporting the
availability of quotation information in the over-the-counter equity
securities market.

B. Self-Regulatory Organization's Statement on Burden on Competition

    FINRA does not believe that the proposed rule change will result in
any burden on competition that is not necessary or appropriate in
furtherance of the purposes of the Exchange Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    Written comments were neither solicited nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule change does not:
    (i) Significantly affect the protection of investors or the public
interest;
    (ii) impose any significant burden on competition; and
    (iii) become operative for 30 days from the date on which it was
filed, or such shorter time as the Commission may designate, if
consistent with the protection of investors and the public interest, it
has become effective pursuant to Section 19(b)(3)(A) of the Act \11\
and Rule 19b-4(f)(6) thereunder.\12\
---------------------------------------------------------------------------

    \11\ 15 U.S.C. 78s(b)(3)(A).
    \12\ 17 CFR 240.19b4(f)(6). In addition, Rule 19b-4(f)(6)(iii)
requires the self-regulatory organization to submit to the
Commission written notice of its intent to file the proposed rule
change, along with a brief description and text of the proposed rule
change, at least five business days prior to the date of filing of
the proposed rule change, or such shorter time as designated by the
Commission. FINRA has satisfied this requirement.

---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an e-mail to<EMAIL_ADDRESS>Please include
File Number SR-FINRA-2011-019 on the subject line.

Paper Comments

     Send paper comments in triplicate to Elizabeth M. Murphy,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

    All submissions should refer to File Number SR-FINRA-2011-019. This
file number should be included on the subject line if e-mail is used.
To help the Commission process and review your comments more
efficiently, please use only one method. The Commission will post all
comments on the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments,
all written statements with respect to the proposed rule change that
are filed with the Commission, and all written communications relating
to the proposed rule change between the Commission and any person,
other than those that may be withheld from the public in accordance
with the provisions of 5 U.S.C. 552, will be available for Web site
viewing and printing in the Commission's Public Reference Room on
official business days between the hours of 10 a.m. and 3 p.m. Copies
of such filing also will be available for inspection and copying at the
principal office of the Exchange. All comments received will be posted
without change; the Commission does not edit personal identifying
information from submissions. You should submit only information that
you wish to make available publicly. All submissions should refer to
File Number SR-FINRA-2011-019 and should be submitted on or before May
31, 2011.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\13\
Elizabeth M. Murphy,
Secretary.
---------------------------------------------------------------------------

    \13\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

[FR Doc. 2011-11325 Filed 5-9-11; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 83, Number 11 (Wednesday, January 17, 2018)]
[Notices]
[Pages 2442-2444]
[FR Doc No: 2018-00740]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Sunshine Act Meeting Notice

    The following notice of meeting is published pursuant to section
3(a) of the government in the Sunshine Act (Pub. L. 94-409), 5 U.S.C.
552b:

AGENCY HOLDING MEETING: Federal Energy Regulatory Commission.

DATE AND TIME: January 18, 2018, 10:00 a.m.

PLACE: Room 2C, 888 First Street NE, Washington, DC 20426.

STATUS: Open.

MATTERS TO BE CONSIDERED: Agenda, * NOTE--Items listed on the agenda
may be deleted without further notice.

CONTACT PERSON FOR MORE INFORMATION: Kimberly D. Bose, Secretary,
Telephone<PHONE_NUMBER>. For a recorded message listing items struck
from or added to the meeting, call<PHONE_NUMBER>.
    This is a list of matters to be considered by the Commission. It
does not include a listing of all documents relevant to the items on
the agenda. All public documents, however, may be viewed on line at the
Commission's website at http://ferc.capitolconnection.org/ sing the
eLibrary link, or may be examined in the Commission's Public Reference
Room.

                                                 1039th--Meeting
                                 [Regular meeting January 18, 2018; 10:00 a.m.]
----------------------------------------------------------------------------------------------------------------
        Item No.                     Docket No.                                    Company
----------------------------------------------------------------------------------------------------------------
                                                 ADMINISTRATIVE
----------------------------------------------------------------------------------------------------------------
A-1.....................  AD18-1-000......................  Agency Administrative Matters.
A-2.....................  AD18-2-000......................  Customer Matters, Reliability, Security and Market
                                                             Operations.
----------------------------------------------------------------------------------------------------------------
                                                    ELECTRIC
----------------------------------------------------------------------------------------------------------------
E-1.....................  ER18-1-000, ER18-1-001..........  California Independent System Operator Corporation.
E-2.....................  RM17-13-000.....................  Supply Chain Risk Management Reliability Standards.
E-3.....................  RM17-12-000.....................  Emergency Preparedness and Operations Reliability
                                                             Standards.
E-4.....................  ER16-2217-005...................  Logan Generating Company, L.P.
                          ER17-2515-001...................  Chambers Cogeneration, Limited Partnership.
E-5.....................  ER17-603-000....................  Bear Swamp Power Company LLC.

E-6.....................  ER17-1459-000, ER06-615-000,      California Independent System Operator Corporation.
                           ER02-1656-027, ER02-1656-029,
                           ER02-1656-030, ER02-1656-031.
E-7.....................  ER17-2113-000...................  Midcontinent Independent System Operator, Inc.
E-8.....................  ER16-2493-002...................  South Carolina Electric & Gas Company.
E-9.....................  ER16-1169-001...................  Ameren Illinois Company.
E-10....................  ER16-1251-003...................  Entergy Louisiana, LLC.
                          ER13-1508-004...................  Entergy Louisiana, LLC, Entergy Texas, Inc. and
                                                             Entergy New Orleans, Inc.
E-11....................  ER17-2495-000...................  Southwest Power Pool, Inc.
E-12....................  ER17-2579-000...................  Entergy Arkansas, Inc.
                          ER15-1436-000...................  Entergy Gulf States Louisiana, L.L.C.
                          ER15-1453-000...................  Entergy Louisiana, LLC.
                          ER16-1528-000...................  Entergy Mississippi, Inc.
                          (consolidated)..................  Entergy New Orleans, Inc.
                                                            Entergy Texas, Inc.
                          ER17-827-000....................  Midcontinent Independent System Operator, Inc.
E-13....................  TX17-1-000......................  Wheatridge Wind Energy, LLC.
E-14....................  EL16-89-000, EL17-40-000, ER06-   Virginia Electric and Power Company.
                           554-000, ER17-512-000, ER17-512-
                           001, ER17-512-002, ER17-512-003.
E-15....................  Omitted.........................
E-16....................  Omitted.........................
E-17....................  EL16-100-000, ER14-1193-003.....  West Deptford Energy, LLC.
E-18....................  ER14-874-001, EL18-25-000.......  Calpine Bethlehem, LLC.
                          ER14-875-001, ER17-2566-000.....  Calpine Mid-Atlantic Generation, LLC.
                          ER12-954-003....................  Calpine Mid Merit, LLC.
                          ER14-873-001, ER15-2495-001.....  Calpine New Jersey Generation, LLC.
                          ER15-2735-003...................  Garrison Energy Center LLC.
                          ER10-2214-003...................  Zion Energy LLC.
E-19....................  ER17-1236-000, ER17-1236-001....  PJM Interconnection, L.L.C.
E-20....................  ER17-419-000, ER17-419-003......  PJM Interconnection, L.L.C.
E-21....................  ER16-2401-000, EL16-96-000......  PJM Interconnection, L.L.C.
E-22....................  ER15-623-010, EL15-29-006.......  PJM Interconnection, L.L.C.
                          EL15-41-002.....................  Essential Power Rock Springs, LLC, Essential Power
                                                             OPP, LLC and Lakewood Cogeneration, L.P. v. PJM
                                                             Interconnection, L.L.C.
E-23....................  EC17-49-001.....................  GridLiance West Transco LLC.
E-24....................  EL16-64-001.....................  Belmont Municipal Light Department, Braintree
                                                             Electric Light Department, Concord Municipal Light
                                                             Plant, Georgetown Municipal Light Department,
                                                             Groveland Electric Light Department, Hingham
                                                             Municipal Lighting Plant, Littleton Electric Light
                                                             & Water Department, Middleborough Gas & Electric
                                                             Department, Middleton Electric Light Department,
                                                             Reading Municipal Light Department, Rowley
                                                             Municipal Lighting Plant, Taunton Municipal
                                                             Lighting Plant, and Wellesley Municipal Light Plant
                                                             v. Central Maine Power Company, Emera Maine
                                                             (formerly known as Bangor Hydro- Electric Company),
                                                             Eversource Energy Service Company and its operating
                                                             company affiliates: The Connecticut Light and Power
                                                             Company, Western Massachusetts Electric Company,
                                                             Public Service Company of New Hampshire, and NSTAR
                                                             Electric Company, New England Power Company, New
                                                             Hampshire Transmission LLC, The United Illuminating
                                                             Company, Fitchburg Gas and Electric Light Company
                                                             and Vermont Transco, LLC.
E-25....................  EL16-107-001....................  Southern Maryland Electric Cooperative, Inc. and
                                                             Choptank Electric Cooperative, Inc.
E-26....................  EL15-47-002.....................  NextEra Desert Center Blythe, LLC v. California
                                                             Independent System Operator Corporation.
----------------------------------------------------------------------------------------------------------------
                                                       GAS
----------------------------------------------------------------------------------------------------------------
G-1.....................  OR17-11-000.....................  Wood River Pipe Lines LLC.
G-2.....................  IS17-498-000, IS17-498-001, IS17- Leveret Pipeline Company LLC.
                           499-000, IS17-499-001, IS17-506-
                           000, IS17-506-001.
                          IS17-500-000, IS17-500-001, IS17- Mid-America Pipeline Company, LLC.
                           501-000, IS17-501-001.
G-3.....................  RP17-944-000....................  Equitrans, L.P.
----------------------------------------------------------------------------------------------------------------
                                                      HYDRO
----------------------------------------------------------------------------------------------------------------
H-1.....................  P-2485-076......................  FirstLight Hydro Generating Company.
H-2.....................  P-12569-015.....................  Public Utility District No. 1 of Okanogan County,
                                                             Washington.
----------------------------------------------------------------------------------------------------------------
                                                  CERTIFICATES
----------------------------------------------------------------------------------------------------------------
C-1.....................  CP17-58-000.....................  Transcontinental Gas Pipe Line Company, LLC.

C-2.....................  CP13-520-000....................  EQT Gathering LLC.
----------------------------------------------------------------------------------------------------------------

    Dated: January 11, 2018.
Kimberly D. Bose,
Secretary.

    A free webcast of this event is available through http://ferc.capitolconnection.org/. Anyone with internet access who desires
to view this event can do so by navigating to www.ferc.gov's
Calendar of Events and locating this event in the Calendar. The
event will contain a link to its webcast. The Capitol Connection
provides technical support for the free webcasts. It also offers
access to this event via television in the DC area and via phone
bridge for a fee. If you have any questions, visit http://ferc.capitolconnection.org/ or contact Danelle Springer or David
Reininger at<PHONE_NUMBER>.
    Immediately following the conclusion of the Commission Meeting,
a press briefing will be held in the Commission Meeting Room.
Members of the public may view this briefing in the designated
overflow room. This statement is intended to notify the public that
the press briefings that follow Commission meetings may now be
viewed remotely at Commission headquarters, but will not be telecast
through the Capitol Connection service.

[FR Doc. 2018-00740 Filed 1-12-18; 11:15 am]
 BILLING CODE 6717-01-P


Amendment to DER for MRID 43293901 - Chronic Neurotoxicity Screening Battery [Rat]
[2,4-DICHLOROPHENOXYACETIC ACID]

This amendment provides an EXECUTIVE SUMMARY and data tables to upgrade the original DER [Document No. 011614].

EPA Reviewer: Linda L. Taylor, Ph.D.
Reregistration Branch I, Health Effects Division (7509C)
EPA Secondary Reviewer: Whang Phang, Ph.D.
Reregistration Branch I, Health Effects Division (7509C)
TXR# 0051360

                        AMENDED DATA EVALUATION RECORD

STUDY TYPE: chronic neurotoxicity - rat 	§ 82-7/OPPTS 870.6200
P.C. CODE: 030001	REREGISTRATION CASE NO.: 818706
CASWELL NO.: 315	CAS NO.: 94-75-7
TEST MATERIAL (PURITY): 2,4-Dichlorophenoxyacetic acid [96.7%]
SYNONYMS: 2,4-D
SPONSOR: Industry Task Force II on 2,4-D Research Data

CITATION: Mattsson, J. L., Jeffries, T. K., Yano, B. L. (1994).  2,4-Dichlorophenoxyacetic acid: Subchronic Neurotoxicity Study in Fischer 344 Rats. The Toxicology Research Laboratory, Dow Chemical Co.; Study No. K-002372-064N, June 28, 1994. MRID 43293901. Document No. 011614. Unpublished.

Jeffries, T. K., Yano, B. L., and Ormand, J. R. (1995). 2,4-Dichlorophenoxyacetic acid: Chronic Toxicity/Oncogenicity Study in Fischer 344 Rats. 1-Year Interim Report. The Toxicology Research Laboratory, Dow Chemical Co.; Study No. K-002372-064, June 23, 1993. MRID 43293901. Document No. 011614. Unpublished.

EXECUTIVE SUMMARY: In this chronic toxicity/carcinogenicity study with a chronic neurotoxicity screening battery substudy [MRID 43293901], 50 Fischer 344 rats/sex/group [main study]; 15/sex/group [substudy] were administered 2,4-dichlorophenoxyacetic acid [96.4%] via the diet for up to 24 months at concentrations of 0 [basal diet], 5 mg/kg/day, 75 mg/kg/day, and 150 mg/kg/day [achieved doses were 4.6, 71.2, and 141.1 mg/kg/day [males] and 4.6, 68.0, and 138.9 mg/kg/day [females], respectively. Additionally, 10 rats/sex/group were sacrificed at 12 months [interim sacrifice]. NOTE: This DER presents the results of the interim [one-year] sacrifice and neurotoxicity substudy.

There were no treatment-related deaths or clinical signs of toxicity. Decreased body weight was observed throughout the first year of the study at the high-dose level in both sexes [males 91%/females 88% of control at the interim sacrifice] and at the mid-dose level in females [94% of control at the interim sacrifice]. At 90 days, the decrease in body weight was very slight in the high-dose males [96% of control] and somewhat greater in the mid- [95% of control] and high-dose [90% of control] females. Body-weight gains were decreased throughout the first year at the mid- and high-dose levels in both sexes, although statistical significance was not always attained in males at the mid-dose level [2-week interval (males: mid-dose 90%/high-dose 84%; females: mid-dose 81%/high-dose 63% of control); 3-month interval (males: mid-dose 98%/high-dose 88%; females: mid-dose 87%/high-dose 75% of control); and 1-year interval (males: mid-dose 95%/high-dose 82%; females: mid-dose 89%/high-dose 73% of control). Consistent with the decreased body-weight gains was a slight decrease in food consumption, which was observed in both sexes at the high-dose level.

Ophthalmology findings were comparable among the groups at the interim sacrifice. Decreased RBC [mid- and high-dose females (6 & 12 months) and high-dose males (12 months)], HCT [mid- and high-dose females and high-dose  males (6 & 12 months)], HGB  [high-dose females (6 months)], WBC 9high-dose females (6 months)], and platelet counts [mid- and high-dose females and high-dose males (6 & 12 months) were observed. A dose-related increase in aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase was observed in the mid- and high-dose males at 6 months but not at 12 months. The mid- and high-dose females displayed a dose-related increase in alkaline phosphatase values at both the 6 and 12-month intervals. Cholesterol levels were decreased in the mid- (males at 12 months only) and high-dose rats of both sexes at both time intervals. T4 values were decreased at both time points in both sexes at the mid- and high-dose levels, although the mid-dose males at 6 months did not attain statistical significance. The only urinalysis finding was a decrease in specific gravity , which was observed in both sexes and time points at the mid- and high-dose levels.

Thyroid weights [absolute and relative] were statistically-significantly  increased in the mid-dose females [20% greater than control] and in both sexes at the high-dose level [20% greater than control] at the 12-month interim sacrifice. Decreased testes weights [absolute and relative to brain] were observed at the high-dose level at 12 months [15% lower than control]. Kidney weights [absolute and relative] were increased at the 12-months sacrifice in males at the mid- [7%-12% greater than control] and high-dose [8%-16% greater than control] levels [dose-related].

Gross pathology findings included decreased fat in high-dose females [4/10] and multifocal pale foci in the lungs [1/10 mid-dose, 10/10 high-dose females]. Microscopically, there were increased incidences of lesions in the bone marrow [decreased hematopoiesis in high-dose females], eyes [bilateral retina degeneration in 1 male and 10 females at high dose], kidney [proximal tubule degeneration in mid- and high-dose males and females], liver [altered tinctorial properties in mid-dose females and both sexes at high dose], lungs [multifocal , subacute to chronic inflammation (mid-dose females, both sexes at high dose), alveolar histiocytosis in females at high dose], adipose tissue [atrophy in mid- and high-dose females], testes [atrophy at high dose], and thyroid [decreased secretory material, epithelial cells-high-dose females].

The NOAEL is 5 mg/kg/day. The LOAEL of 75 mg/kg/day is based on decreased body weight (females)/body-weight gain (both sexes), alterations in hematology [decreased RBC, HCT, and platelets (females)], clinical chemistry parameters [increased alanine and aspartate aminotransferases (males), alkaline phosphatase (both sexes), decreased cholesterol (both sexes), and decreased T4 (both sexes)], and urinalysis [decreased specific gravity (both sexes)], increased kidney weights (males), increased incidence of degeneration of the descending proximal tubules (both sexes), hepatocellular hypertrophy with altered tinctorial properties (females), lung inflammation (females), adipose tissue atrophy (females). At the high-dose level, there also were microscopic lesions in the eyes (both sexes), liver (males), testes (males), thyroid (females), and lungs (males).

NEUROTOXICITY STUDY

No treatment-related, hand-held, FOB observations were noted at any of the evaluation periods. Relative forelimb grip strength was significantly increased in both sexes at the high-dose level, but there was no treatment-related change in absolute grip strength. There was no treatment-related effect on motor activity. In agreement with the chronic toxicity portion of the study, an increased incidence of bilateral retinal degeneration was observed in the high-dose females.

The NOAEL for neurotoxicity is 75 mg/kg/day, based on increased relative forelimb grip strength and increased incidence of bilateral retinal degeneration at the LOAEL of 150 mg/kg/day.

This chronic toxicity/neurotoxicity study in the rat is classified ACCEPTABLE/Guideline, and it satisfies the guideline requirement [OPPTS 870. 6200; §82-7] for a subchronic neurotoxicity study in the rat.

                     Table 1. Body-Weight/Body-Weight Gain

                            Parameter/Day/Sex/Dose

                                  0 mg/kg/day

                                  5 mg/kg/day

                                 75 mg/kg/day

                                 150 mg/kg/day

                                BODY WEIGHT [g]
                                     MALES
                                      -2
                                       6
                                      27
                                      90
                                      365

                                    FEMALES
                                      -2
                                       6
                                      27
                                      90
                                      365

                                  197.6+-11.5
                                  217.5+-13.1
                                  246.0+-15.9
                                  308.3+-22.1
                                  409.8+-28.5

                                  129.2+-4.9
                                  139.2+-5.6
                                  160.5+-7.4
                                  187.0+-9.1
                                  217.5+-10.9

                                  197.6+-9.9
                                  216.8+-12.0
                                  247.7+-13.9
                                  311.8+-20.0
                                  415.5+-23.5

                                  127.9+-5.6
                                  138.4+-5.6
                                  160.3+-7.6
                                  186.3+-8.6
                                  217.6+-12.4

                                  197.1+-9.2
                                  214.4+-11.1
                                  243.3+-14.6
                                  305.3+-20.4
                                  400.0+-30.2

                                126.6+-5.0*[98]
                                134.1+-5.7*[96]
                                151.1+-6.3*[94]
                                176.8+-8.0*[95]
                               205.6+-11.8*[95]

                                  197.8+-10.6
                                  213.5+-11.9
                               239.5+-14.6*[97]
                               295.2+-19.4*[96]
                               372.5+-26.6*[91]

                                126.2+-5.2*[98]
                                130.7+-5.1*[94]
                                145.8+-6.1*[91]
                                169.3+-7.3*[91]
                                190.7+-9.1*[88]

                             BODY-WEIGHT GAIN [g]
                                     MALES
                                     -2-6
                                     -2-13
                                     -2-90
                                    -2-365

                                    FEMALES
                                     -2-6
                                     -2-13
                                     -2-90
                                    -2-365

                                   19.9+-4.1
                                   33.0+-5.7
                                  110.7+-15.0
                                  212.2+-20.4

                                   10.0+-2.7
                                   17.5+-3.4
                                   57.8+-7.6
                                  88.3+-10.4

                                   19.2+-5.8
                                   33.3+-5.0
                                  114.3+-14.7
                                  217.9+-19.2

                                   10.5+-2.8
                                  19.1+-3.1*
                                   58.4+-6.5
                                  89.7+-10.7

                                17.3+-3.5*[87]
                                29.8+-6.4*[90]
                                  108.3+-14.6
                               202.4+-25.8*[95]

                                 7.5+-3.5*[75]
                                14.2+-3.3*[81]
                                50.2+-6.6*[87]
                                79.0+-10.6*[89]

                                15.7+-3.6*[79]
                                28.0+-5.6*[85]
                                97.4+-12.9*[88]
                               175.0+-20.5*[82]

                                 4.5+-3.7*[45]
                                11.0+-3.5*[63]
                                43.1+-5.9*[75]
                                64.5+-8.0*[73]
                         [% of control]; data from Tables 9-12 [pages 96-107] of the report

                   Table 2. Clinical Pathology Data - MALES

                             Dose/Month/Parameter

                                  0 mg/kg/day

                                  5 mg/kg/day

                                 75 mg/kg/day

                                 150 mg/kg/day

                            platelets [x10E3/cumm]
                                       6
                                      12

                                    615+-41
                                    586+-65

                                    613+-32
                                    598+-25

                                    604+-36
                                    572+-33

                                 529+-25*[86]
                                 474+-45*[81]

                               RBC[ x10E6/cumm]
                                       6
                                      12

                                  9.82+-0.35
                                  9.31+-0.28

                                  9.85+-0.30
                                  9.20+-0.22

                                  10.11+-0.26
                                  9.36+-0.19

                                  9.60+-0.34
                                8.55+-0.35*[92]

                                  HGB [g/dL]
                                       6
                                      12

                                   17.2+-0.5
                                   15.0+-0.5

                                   17.2+-0.6
                                   15.1+-0.3

                                   17.5+-0.5
                                   15.1+-0.3

                                   17.1+-0.4
                                   14.9+-0.7

                                    HCT {%}
                                       6
                                      12

                                   61.9+-2.2
                                   58.5+-1.8

                                   61.9+-2.1
                                   58.1+-1.5

                                   62.6+-1.7
                                   58.2+-1.2

                                59.3+-1.7*[86]
                                55.3+-2.7*[95]

                        alanine aminotransferase [U/L]
                                       6
                                      12

                                     65+-8
                                    66+-18

                                    63+-14
                                    61+-15

                                 120+-61*[185]
                                 91+-21*[138]

                                 122+-26*[188]
                                    68+-15

                       aspartate aminotransferase [U/L]
                                       6
                                      12

                                    116+-16
                                    106+-21

                                    111+-21
                                    95+-20

                                 162+-64*[140]
                                 132+-39 [125]

                                 172+-27*[148]
                                    103+-15

                          blood urea nitrogen [mg/dL]
                                       6
                                      12

                                     17+-1
                                     15+-2

                                     17+-1
                                  13+-1 [87]

                                     18+-1
                                     14+-2

                                     18+-3
                                  13+-1 [87]

                              creatinine [mg/dL]
                                       6
                                      12

                                   0.7+-0.0
                                   0.6+-0.0

                                   0.8+-0.1
                                   0.6+-0.0

                                   0.8+-0.1
                                0.7+-0.1*[117]

                                0.9+-0.1*[129]
                                0.7+-0.1*[117]

                          alkaline phosphatase [U/L]
                                       6
                                      12

                                     73+-7
                                     57+-4

                                     75+-7
                                     57+-5

                                 85+-11*[116]
                                     58+-6

                                  92+-9*[126]
                                     55+-7

                                glucose [mg/dL]
                                       6
                                      12

                                    112+-16
                                    117+-9

                                    116+-17
                                    124+-4

                                    108+-15
                                    111+-7

                                 102+-15 [91]
                                 100+-10*[85]

                              cholesterol [mg/dL]
                                       6
                                      12

                                    86+-10
                                    87+-17

                                     80+-3
                                    83+-11

                                    84+-10
                                  69+-11*[79]

                                  71+-8*[83]
                                  53+-6*[61]

                             triglycerides [mg/dL]
                                       6
                                      12

                                    140+-27
                                    101+-29

                                    139+-36
                                    105+-29

                                    171+-38
                                  89+-21 [88]

                                    129+-12
                                  70+-9*[69]
                             [% of control]; n=10; * p<0.05;
                              data from Tables 15-16 [pages 112-115] and Tables23-26 [pages 128-144] of the report

                  Table 3. Clinical Pathology Data - FEMALES

                             Dose/Month/Parameter

                                  0 mg/kg/day

                                  5 mg/kg/day

                                 75 mg/kg/day

                                 150 mg/kg/day

                            platelets [x10E3/cumm]]
                                       6
                                      12
                                      18
                                      24

                                    599+-39
                                    583+-23
                                    591+-40
                                    562+-92

                                    609+-44
                                 548+-120 [94]
                                    613+-47
                                   549+-139

                                 461+-30*[77]
                                 471+-48*[81]
                                 496+-33*[84]
                                   551+-130

                                 403+-30*[67]
                                 486+-44*[84]
                                 491+-33*[83]
                                 523+-135 [93]

                               RBC[ x10E6/cumm]
                                       6
                                      12
                                      18
                                      24

                                  9.11+-0.21
                                  8.37+-0.29
                                  8.61+-0.18
                                  8.28+-1.60

                                  9.05+-0.22
                                  8.46+-0.50
                                  8.41+-0.21
                                7.91+-1.53 [96]

                                8.71+-0.16*[96]
                                7.78+-0.48*[93]
                                7.83+-0.93*[91]
                                7.44+-1.49*[90]

                                  8.22+-0.28
                                  7.59+-0.25
                                7.61+-0.25*[88]
                                7.01+-1.77*[85]

                                  HGB [g/dL]
                                       6
                                      12
                                      18
                                      24

                                   17.2+-0.3
                                   14.8+-0.4
                                   16.1+-0.3
                                   14.7+-2.6

                                   17.1+-0.3
                                   15.0+-0.9
                                15.8+-0.3*[98]
                                   14.6+-1.9

                                   16.9+-0.4
                                   14.4+-0.9
                                14.8+-2.1*[92]
                                 13.9+-2.3[95]

                                16.6+-0.4*[97]
                                   14.5+-0.6
                                14.9+-0.3*[93]
                                13.3+-3.0 [90]

                                  HCT [&]
                                       6
                                      12
                                      18
                                      24

                                   60.6+-1.2
                                   57.3+-1.9
                                   46.8+-1.2
                                   43.6+-7.6

                                   60.3+-2.0
                                   57.7+-3.4
                                   xx.5+-0.9
                                   43.6+-4.3

                                58.4+-1.2*[96]
                                52.6+-3.1*[92]
                                   44.0+-4.4
                                41.6+-6.4 [95]

                                55.9+-2.3*[92]
                                51.8+-2.2*[90]
                                43.5+-1.4*[93]
                                40.9+-6.5 [94]

                        alanine aminotransferase [U/L]
                                       6
                                      12
                                      18
                                      24

                                     51+-8
                                    37+-10
                                     42+-8
                                    48+-28

                                    50+-19
                                    42+-20
                                     40+-5
                                    50+-28

                                    56+-16
                                     37+-8
                                    34+-12
                                    61+-78

                                    40+-6*
                                    33+-10
                                     36+-4
                                    55+-62

                       aspartate aminotransferase [U/L]
                                       6
                                      12
                                      18
                                      24

                                    96+-11
                                    71+-15
                                    80+-15
                                    92+-60

                                    101+-35
                                    80+-34
                                    70+-12
                                   105+-110

                                    103+-14
                                    63+-10
                                     72+-8
                                136+-291 [148]

                                    98+-13
                                    68+-16
                                     81+-9
                                134+-216 [146]

                          blood urea nitrogen [mg/dL]
                                       6
                                      12
                                      18
                                      24

                                     20+-3
                                     14+-1
                                     20+-1
                                    20+-10

                                     20+-3
                                     14+-1
                                     18+-2
                                     16+-2

                                     21+-3
                                     15+-2
                                     21+-3
                                     20+-6

                                     21+-2
                                     13+-2
                                     19+-2
                                    25+-28

                              creatinine [mg/dL]
                                       6
                                      12
                                      18
                                      24

                                   0.8+-0.1
                                   0.7+-0.1
                                   0.7+-0.0
                                   0.7+-0.1

                                   0.8+-0.1
                                   0.7+-0.1
                                   0.7+-0.0*
                                   0.7+-0.0

                                0.9+-0.1*[113]
                                0.8+-0.1*[114]
                                0.9+-0.0*[129]
                                0.8+-0.1*[114]

                                0.9+-0.1*[113]
                                   0.7+-0.0*
                                0.9+-0.1*[129]
                                0.8+-0.1*[114]

                          alkaline phosphatase [U/L]
                                       6
                                      12
                                      18
                                      24

                                     47+-9
                                     32+-3
                                     37+-5
                                    47+-28

                                     46+-4
                                     32+-6
                                    40+-10
                                    63+-50

                                  59+-7*[126]
                                  47+-8*[147]
                                 69+-48*[186]
                                 84+-77*[179]

                                 73+-16*[155]
                                 54+-10*[169]
                                 76+-18*[205]
                                 99+-52*[211]

                                glucose [mg/dL]
                                       6
                                      12
                                      18
                                      24

                                    96+-12
                                    109+-8
                                     97+-6
                                    94+-18

                                    96+-10
                                    114+-10
                                    103+-10
                                    94+-11

                                  88+-9 [92]
                                    112+-9
                                  86+-11*[89]
                                  82+-18*[87]

                                   72+-8[75]
                                    113+-11
                                  79+-6*[81]
                                  77+-11*[82]

                              cholesterol [mg/dL]
                                       6
                                      12
                                      18
                                      24

                                    116+-11
                                    105+-13
                                    155+-9
                                    169+-38

                                    123+-5
                                    110+-16
                                    148+-14
                                    166+-29

                                  81+-6*[70]
                                  54+-7*[51]
                                  76+-11*[49]
                                 104+-57*[62]

                                  76+-8*[66]
                                  57+-7*[54]
                                  81+-4*[52]
                                 109+-36*[64]

                             triglycerides [mg/dL]
                                       6
                                      12
                                      18
                                      24

                                    77+-14
                                     52+-8
                                    136+-46
                                    183+-85

                                    88+-22
                                    56+-18
                                    129+-34
                                    180+-98

                                    88+-16
                                     54+-6
                                  93+-14*[68]
                                 126+-52*[69]

                                     83+-6
                                     56+-4
                                  88+-14*[65]
                                 105+-21*[57]
                             [% of control]; n=10 [6, 12, 18 months]/n=20 [24 months]; * p<0.05;
                               data from Tables 15-16 [pages 112-115] and Tables23-26 [pages 128-144] of the report

                         Table 4.  T4 Results [ug/dL]

                                Dose/Sex/Month

                                  0 mg/kg/day

                                  5 mg/kg/day

                                 75 mg/kg/day

                                 150 mg/kg/day

                                     MALES
                                       6
                                      12

                                   3.2+-0.5
                                   3.0+-0.4

                                   3.4+-0.6
                                   3.1+-0.3

                                 2.7+-0.2 [84]
                                 2.6+-0.3*[87]

                                 2.1+-0.9*[66]
                                 0.9+-0.2*[30]

                                   FE MALES
                                       6
                                      12

                                   2.6+-0.5
                                   2.3+-0.4

                                   2.7+-0.4
                                   2.2+-0.4

                                 1.1+-0.3*[42]
                                 0.8+-0.2*[35]

                                 0.9+-0.2*[35]
                                 0.7+-0.2*[30]
                       [% of control]; n=10 [6, 12, 18 months]/n=20 [24 months]; * p<0.05; data from  Tables 27-28 [pages 136-139] of the report

                Table 5. Organ Weight Data - MALES [12 months]

                                  Dose/Organ

                                  0 mg/kg/day

                                  5 mg/kg/day

                                 75 mg/kg/day

                                 150 mg/kg/day

                                     brain
                                 absolute [g]
                           relative-to-body [g/100]

                                 2.039+-0.105
                                 0.536+-0.016

                                 2.000+-0.066
                                 0.515+-0.017

                                 2.025+-0.062
                                 0.557+-0.040

                               1.988+-0.095 [97]
                                 0.056+-0.031

                                     liver
                                 absolute [g]
                           relative-to-body [g/100]
                           relative-to-brain [g/100]

                                 9.508+-0.662
                                 2.496+-0.062
                                 466.26+-19.50

                                 9.630+-0.661
                                 2.476+-0.111
                                 481.45+-30.38

                               8.543+-0.677*[90]
                               2.338+-0.080*[94]
                              421.69+-28.47*[90]

                                 8.942+-0.370
                                 2.520+-0.125
                                 450.74+-30.15

                                    kidney
                                 absolute [g]
                           relative-to-body [g/100]
                           relative-to-brain [g/100]

                                 2.231+-0.105
                                 0.586+-0.019
                                 109.47+-3.49

                                 2.255+-0.111
                                 0.580+-0.017
                                 112.75+-4.24

                              2.391+-0.150*[107]
                              0.655+-0.026*[112]
                              118.09+-6.45*[108]

                              2.409+-0.125*[108]
                              0.678+-0.013*[116]
                              121.32+-6.73*[111]

                                    testes
                                 absolute [g]
                           relative-to-body [g/100]
                           relative-to-brain [g/100]

                                 3.158+-0.293
                                 0.832+-0.092
                                 155.10+-14.49

                                 3.247+-0.128
                                 0.836+-0.032
                                 162.35+-5.67

                                 3.198+-0.193
                                 0.877+-0.052
                                 157.96+-8.63

                               2.669+-0.540*[85]
                               0.748+-0.139 [90]
                              134.09+-26.32*[86]

                                    thyroid
                                 absolute [g]
                           relative-to-body [g/100]
                           relative-to-brain [g/100]

                                 0.027+-0.002
                                0.0071+-0.0006
                                1.3178+-0.1091

                                 0.025+-0.002
                                0.0064+-0.0006
                                1.2517+-0.1068

                                 0.026+-0.003
                                0.0070+-0.0006
                                1.2582+-0.1198

                              0.032+-0.003*[119]
                             0.0091+-0.0009*[128]
                             1.6308+-0.1805*[124]

                           terminal body weight [g]

                                  380.8+-21.9

                                  388.6+-14.8

                                  365.5+-28.3

                               355.4+-18.8*[93]
                               [% of control]; n=10; * p<0.05; data from Tables 27-28 [pages 136-139] of the report

               Table 6. Organ Weight Data - FEMALES [12 months]

                                  Dose/Organ

                                  0 mg/kg/day

                                  5 mg/kg/day

                                 75 mg/kg/day

                                 150 mg/kg/day

                                     brain
                                 absolute [g]
                           relative-to-body [g/100]

                                 1.833+-0.058
                                 0.926+-0.037

                                 1.852+-0.051
                                 0.887+-0.045

                                 1.837+-0.049
                                 0.942+-0.060

                                 1.796+-0.056
                            1.013+-0.056*[109]

                                     liver
                                 absolute [g]
                           relative-to-body [g/100]
                           relative-to-brain [g/100]

                                 5.294+-0.350
                                 2.673+-0.154
                                 288.80+-15.35

                                 5.560+-0.418
                                 2.655+-0.125
                                 300.34+-23.66

                                 5.354+-0.445
                                 2.735+-0.118
                                 291.59+-24.39

                                 5.499+-0.422
                              3.094+-0.171*[116]
                              305.97+-19.45 [106]

                                    kidney
                                 absolute [g]
                           relative-to-body [g/100]
                           relative-to-brain [g/100]

                                 1.440+-0.069
                                 0.727+-0.029
                                  78.55+-2.53

                                 1.481+-0.112
                                 0.708+-0.041
                                  80.05+-6.75

                                 1.558+-0.092
                              0.797+-0.036*[110]
                               84.89+-5.60 [108]

                              1.544+-0.148 [107]
                              0.868+-0.061*[119]
                               85.94+-7.63*[109]

                                    ovaries
                                 absolute [g]
                           relative-to-body [g/100]
                           relative-to-brain [g/100]

                                 0.057+-0.013
                                 0.029+-0.006
                                  3.11+-0.70

                                 0.056+-0.012
                                 0.027+-0.005
                                  3.03+-0.64

                                 0.058+-0.005
                                 0.029+-0.003
                                  3.13+-0.24

                               0.052+-0.009 [91]
                                 0.029+-0.005
                                2.87+-0.44 [92]

                                    thyroid
                                 absolute [g]
                           relative-to-body [g/100]
                           relative-to-brain [g/100]

                                 0.018+-0.001
                                0.0093+-0.0008
                                1.0052+-0.0872

                                 0.019+-0.002
                                0.0091+-0.0010
                                1.0276+-0.1280

                              0.022+-0.001*[122]
                             0.0111+-0.0006*[119]
                             1.1816+-0.0659*[118]

                              0.022+-0.003*[122]
                             0.0126+-0.0012*[135]
                             1.2463+-0.1265*[124]

                           terminal body weight [g]

                                  198.2+-10.5

                                  209.3+-10.5

                                  195.7+-13.1

                                177.7+-9.8*[90]
                               [% of control];* p<0.05; n=10; data from  Tables 27-28 [pages 136-139] of the report


[Federal Register Volume 81, Number 98 (Friday, May 20, 2016)]
[Notices]
[Pages 31931-31932]
[FR Doc No: 2016-11886]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings #1

    Take notice that the Commission received the following electric
corporate filings:

    Docket Numbers: EC08-126-001.
    Applicants: LS Power Development, LLC, Luminus Management, LLC.
    Description: Request for Suspension of Reporting Obligations, LS
Power Development, LLC and Luminus Management, LLC.
    Filed Date: 5/11/16.
    Accession Number: 20160511-5306.
    Comments Due: 5 p.m. ET 5/26/16.

    Take notice that the Commission received the following exempt
wholesale generator filings:

    Docket Numbers: EG16-98-000.
    Applicants: Paulding Wind Farm III LLC.
    Description: Self-Certification of EWG of Paulding Wind Farm III
LLC.
    Filed Date: 5/13/16.
    Accession Number: 20160513-5046.
    Comments Due: 5 p.m. ET 6/3/16.

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER10-2331-055; ER10-2319-046; ER10-2317-046; ER13-
1351-028; ER10-2330-053.
    Applicants: J.P. Morgan Ventures Energy Corporation, BE Alabama
LLC, BE CA LLC, Florida Power Development LLC, Utility Contract
Funding, L.L.C.
    Description: Notice of Non-Material Change in Status of the
JPMorgan Sellers.
    Filed Date: 5/12/16.
    Accession Number: 20160512-5259.
    Comments Due: 5 p.m. ET 6/2/16.

    Docket Numbers: ER16-1331-001.
    Applicants: Southwest Power Pool, Inc.
    Description: Tariff Amendment: Amended Filing-Clarify Process to
Study Requests for Short-Term Service to be effective 5/31/2016.
    Filed Date: 5/13/16.
    Accession Number: 20160513-5047.
    Comments Due: 5 p.m. ET 6/3/16.

    Docket Numbers: ER16-1689-000.
    Applicants: ArcelorMittal Cleveland LLC.
    Description: Baseline eTariff Filing: Petition for Acceptance of
Market-Based Rate to be effective 6/30/2016.
    Filed Date: 5/13/16.
    Accession Number: 20160513-5001.
    Comments Due: 5 p.m. ET 6/3/16.

    Docket Numbers: ER16-1690-000.
    Applicants: Public Service Company of Colorado.
    Description: Compliance filing: 20160513 ER16-524 CSU Renewable
Energy Credits to be effective 4/16/2016.
    Filed Date: 5/13/16.
    Accession Number: 20160513-5070.
    Comments Due: 5 p.m. ET 6/3/16.

    Docket Numbers: ER16-1691-000.
    Applicants: Escalante Solar III, LLC.
    Description: Compliance filing: Comp. Filing--Amendment to MBR
Tariff Limits. and Exemptions to be effective 7/12/2016.
    Filed Date: 5/13/16.
    Accession Number: 20160513-5072.
    Comments Due: 5 p.m. ET 6/3/16.

    Docket Numbers: ER16-1692-000.
    Applicants: Arizona Public Service Company.
    Description: Section 205(d) Rate Filing: Rate Schedule Nos. 44, 98,
211--Four Corners Acquisition to be effective 12/31/9998.
    Filed Date: 5/13/16.
    Accession Number: 20160513-5076.
    Comments Due: 5 p.m. ET 6/3/16.

    Docket Numbers: ER16-1693-000.
    Applicants: Arizona Public Service Company.
    Description: Section 205(d) Rate Filing: Reassignment of Service
Agreement Nos. 350, 351 and 352 to be effective 4/15/2016.

    Filed Date: 5/13/16.
    Accession Number: 20160513-5077.
    Comments Due: 5 p.m. ET 6/3/16.

    Take notice that the Commission received the following electric
securities filings:

    Docket Numbers: ES16-35-000.
    Applicants: MDU Resources Group, Inc.
    Description: Application of MDU Resources Group, Inc. for
Authorization to issue securities for the Long-Term Performance Based
Incentive Plan.
    Filed Date: 5/12/16.
    Accession Number: 20160512-5266.
    Comments Due: 5 p.m. ET 6/2/16.

    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: May 13, 2016.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2016-11886 Filed 5-19-16; 8:45 am]
BILLING CODE 6717-01-P